Questionnaire

1. The most prevalent symptom in patients with PsA is:

2. There is a small group of patients with PsA who have simultaneous onset of skin and musculoskeletal symptoms; sometimes, musculoskeletal symptoms can occur prior to skin and nail manifestations.

3. Patients with PsA and symptoms of enthesitis and dactylitis have:

4. The EULAR recommends immediate bDMARD therapy for the patient with PsA and with:

5. In cases where the patient with PsA has skin and nail manifestations, the EULAR prefers immediate bDMARD therapy using:

6. Inhibition of IL-17A has the potential for effectively preventing:

7. The SPIRIT-P1 and -P2 trials demonstrated that compared with placebo, IXE treatment resulted in rapid, clinically meaningful and significant improvements across all manifestations of PsA sustained over three years of ongoing therapy in patients who were biologic-naïve or TNFi-IR, with or without concomitant csDMARD therapy.

8. The SPIRIT-H2H trial demonstrated that compared with ADA in biologic-naïve patients with PsA and PsO, IXE-treated patients:

9. Analysis of 21 trials of IXE therapy in adult patients with PsO, PsA and axSpA have demonstrated that the most common TEAEs were:

10. ASAS classification criteria for axSpA include HLA-B27 plus ≥2 of which SpA features?